Inhibrx Biosciences, Inc.
INBX
$82.96
$0.710.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 1,200.00% | -- | -93.88% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1,200.00% | -- | -93.88% | -- |
| Cost of Revenue | -26.63% | -67.08% | -42.25% | -27.80% | 2.20% |
| Gross Profit | 26.63% | 68.95% | 42.25% | 26.46% | -2.52% |
| SG&A Expenses | -33.24% | -93.12% | -39.60% | 309.18% | 0.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.75% | -82.18% | -41.89% | 1.42% | 1.85% |
| Operating Income | 27.75% | 82.98% | 41.89% | -3.19% | -2.12% |
| Income Before Tax | 19.62% | -101.54% | 44.97% | 48.87% | 15.30% |
| Income Tax Expenses | -- | 0.00% | -- | 100.00% | -- |
| Earnings from Continuing Operations | 19.62% | -101.54% | 44.97% | 48.86% | 15.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.62% | -101.54% | 44.97% | 48.86% | 15.30% |
| EBIT | 27.75% | 82.98% | 41.89% | -3.19% | -2.12% |
| EBITDA | 27.82% | 83.34% | 42.52% | -2.75% | -1.13% |
| EPS Basic | 19.68% | -101.46% | 51.48% | 55.27% | 35.45% |
| Normalized Basic EPS | 19.68% | 83.44% | 51.48% | 16.81% | 35.45% |
| EPS Diluted | 19.72% | -101.48% | 51.48% | 55.25% | 35.36% |
| Normalized Diluted EPS | 19.68% | 83.22% | 51.48% | 16.81% | 35.45% |
| Average Basic Shares Outstanding | 0.06% | 5.81% | 13.41% | 14.33% | 31.22% |
| Average Diluted Shares Outstanding | 0.06% | 4.46% | 13.41% | 14.33% | 31.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |